Skip to main content
Premium Trial:

Request an Annual Quote

Patent Pending

On Tuesday, the US Senate voted to approve a bill that would change the US patent system into one that more closely resembles the standard used by the rest of the world, reports The Chronicle of Higher Education's Goldie Blumenstyk. "If enacted, the changes could pressure researchers to publish new findings more quickly than they would otherwise, in order to preserve their intellectual-property rights," she adds. The bill, called the Patent Reform Act of 2011, would change the patent standard from "first to invent" to "first to file." Some in academia worry that this could put more pressure on researchers to publish quickly for fear someone else could beat them to it, Blumenstyk says, especially since a publication by a rival researcher would "block the academics' right to obtain the patent because it would be assumed that they had devised their idea from reading the rival's work." Others say, however, that the worry about rushed publishing is unnecessary, and point to other places like Japan and Europe where "first to file" is already the standard. "Because the patent-reform bill does not consider publications by inventors themselves as prior art, as long as the patent application is filed within a year of the publication, the current legislation ensures that faculty rights to publish are not in conflict with faculty interests in seeking patents on their work," Blumenstyk adds. The US House of Representatives has yet to take up the bill.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.